Expression profiles of miR3181 and miR199a in plasma and placenta of virally suppressed HIV-1 infected Cameroonian pregnant women at delivery.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 24 08 2021
accepted: 09 05 2022
entrez: 20 5 2022
pubmed: 21 5 2022
medline: 25 5 2022
Statut: epublish

Résumé

Human immunodeficiency virus (HIV)-1 infection during pregnancy reduces the transplacental transfer of protective maternal antibodies needed to confer immunity during early postnatal life. However, the mediation of MicroRNA in this dysregulation is not well understood MicroRNAs 3181 and 199a have been shown to mediate neonatal Fc receptor (FcRn)-like transmembrane antibody transfer and endocytosis respectively but their expression levels in the placenta and plasma in women living with HIV have not been extensively investigated. The objective of this study was to determine how the expression levels of miR-3181 and miR-199a in the placenta and plasma are affected in women chronically infected with HIV who are on antiretroviral therapy (ART) and are virally suppressed at delivery. In this pilot case-control study, plasma and placenta biopsies were obtained from 36 (18 HIV+ and 18 HIV-) Cameroonian women at delivery. MicroRNAs 3181 and 199a expression levels were measured using RT-qPCR, data was analyzed using SPSS22.0 and R 3.60, and p values below 0.05 were considered statistically significant. All the HIV-infected women were on known ART regimens and were virally suppressed. There was no significant difference in the levels of miR-3181 (p>0.05) in the placenta and plasma amongst HIV-infected and HIV uninfected women. The expression levels of miR-199a were significantly greater in the plasma compared to the placenta of HIV+ (p = 0.00005) and HIV- (p = 0.027) women. Moreover, there was a significantly higher (p = 0.02) level of miR-199a in the plasma of women with HIV and their uninfected counterparts. Linear regression models adjusted for systolic pressure showed no significant difference (p>0.05) in the levels of miR-199a and miR-3181 in both the placenta and plasma due to HIV infection. Our findings suggest that even though ART uptake and viral suppression might help in maintaining miR3181 and miR199a levels in the placenta of women with HIV at comparative levels to those of their HIV negative counterparts, the significantly higher levels of miR-199a in the plasma of women with HIV compared to the placenta might highlight lurking systemic dangers and requires further investigation.

Identifiants

pubmed: 35594307
doi: 10.1371/journal.pone.0268820
pii: PONE-D-21-27447
pmc: PMC9122233
doi:

Substances chimiques

MicroRNAs 0
mirn199 microRNA, human 0
MIRN3181 microRNA, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0268820

Subventions

Organisme : FIC NIH HHS
ID : R25 TW009345
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Clin Dev Immunol. 2012;2012:985646
pubmed: 22235228
Pediatr Infect Dis J. 2018 Mar;37(3):246-252
pubmed: 28834955
Am J Obstet Gynecol. 2015 Oct;213(4 Suppl):S163-72
pubmed: 26428496
Front Immunol. 2016 Aug 31;7:338
pubmed: 27630640
Lancet Infect Dis. 2016 Jun;16(6):e92-e107
pubmed: 27049574
BMJ Open. 2019 Jun 21;9(6):e023937
pubmed: 31229997
J Mol Biol. 2014 Mar 20;426(6):1178-97
pubmed: 24370931
PLoS One. 2013 Oct 23;8(10):e76729
pubmed: 24194846
Nat Med. 2007 Oct;13(10):1241-7
pubmed: 17906637
Front Immunol. 2016 May 06;7:164
pubmed: 27199989
Int J Mol Sci. 2012;13(7):8449-66
pubmed: 22942713
BMC Cancer. 2016 Nov 14;16(1):887
pubmed: 27842518
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Arch Intern Med. 2006 Feb 27;166(4):405-10
pubmed: 16505259
Pharm Res. 2018 Jan 4;35(1):15
pubmed: 29302759
Placenta. 2012 Sep;33(9):725-34
pubmed: 22721760
Open Forum Infect Dis. 2016 May 10;3(2):ofw092
pubmed: 28487863
Front Immunol. 2016 Sep 28;7:383
pubmed: 27733852
J Cell Sci. 2015 Sep 1;128(17):3197-209
pubmed: 26163491
J Biol Chem. 2014 Mar 14;289(11):7812-24
pubmed: 24469444
Ann Med Health Sci Res. 2014 Sep;4(Suppl 3):S298-301
pubmed: 25364605
PLoS One. 2019 May 1;14(5):e0215825
pubmed: 31042729

Auteurs

Livo F Esemu (LF)

The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.
Centre for Medical Research, Institute Medical Research and Medicinal Plant Studies, Yaounde, Cameroon.
Department of Biomedical Sciences, Faculty of Health Sciences, University of Buea, Buea, Cameroon.

Honore Awanakam (H)

The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.
Department of Biochemistry, University of Yaounde I, Yaounde, Cameroon.

Dieudonne Nanfa (D)

The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.
Department of Biochemistry, University of Yaounde I, Yaounde, Cameroon.

Michael Besong (M)

The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.

Idriss Tsayem (I)

The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.

Celine Nguefeu Nkenfou (CN)

System Biology Laboratory, Chantal Biya International Reference Centre, Yaounde, Cameroon.

Jude Bigoga (J)

The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.
Department of Biochemistry, University of Yaounde I, Yaounde, Cameroon.

Rose Leke (R)

The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.
Centre for Medical Research, Institute Medical Research and Medicinal Plant Studies, Yaounde, Cameroon.

Sobngwi Eugene (S)

The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.

Lishomwa C Ndhlovu (LC)

Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, United States of America.
Division of Infectious Diseases, Weill Cornell Medicine, New York City, New York, United States of America.

Gabriel Ekali Loni (GE)

The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH